Jefferies Reiterates a Buy Rating on Structure Therapeutics (GPCR) With a $79 PT

Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the 13 Small Cap Stocks Analysts Are Bullish On. Jefferies analyst Roger Song maintained a Buy rating on Structure Therapeutics Inc. (NASDAQ:GPCR) on June 5, setting a price target of $79.00.

The analyst reasoned that Structure Therapeutics Inc. (NASDAQ:GPCR) is poised to experience a catalyst-rich H2 2025 as its clinical trials are expected to undergo significant developments. Management expects two Phase 2b readouts in Q4, along with the initiation of the amylin first-in-human study by the end of the year.

A scientist in a lab coat observing a beaker with colored liquid as it bubbles and hisses.

According to Song, these milestones are critical as they can determine the safety and efficacy of the compounds, especially the ‘1290 compound, with the potential to differentiate from competitors.

Structure Therapeutics Inc. (NASDAQ:GPCR) is also exploring strategic partnerships for commercialization and ensuring manufacturing readiness as part of strategic preparations for Phase 3 trials. The analyst considers it well-positioned to capitalize on emerging opportunities and advance its clinical programs, supported by a cash runway extending to 2027.

Structure Therapeutics Inc. (NASDAQ:GPCR) is a clinical-stage global biopharmaceutical company that develops novel oral therapeutics for the treatment of a range of chronic diseases with unmet medical needs. The company’s pipeline includes Aleniglipron GSBR-1290, ACCG-2671, GIPR, GCGR, ANPA-0073, and LTSE-2578.

While we acknowledge the potential of GPCR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.